Paper Details

  1. Home
  2. Paper Details

Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial.

Author: BassettiClaudio L A, FietzeIngo, MaylebenDavid W, McCallWilliam V, PainScott, Seboek KinterDalma

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This analysis further analyzed a phase III trial studying the higher doses of the dual orexin receptor antagonist daridorexant, which showed efficacy in adults with insomnia. The analysis compared the safety and efficacy of daridorexant in patients aged ≥ 65 years ('older adults') to those aged < 65 years ('younger adults').
Paper Details　
Original Abstract of the Article :
The dual orexin receptor antagonist daridorexant, studied in two phase III trials, dose-dependently improved objective and subjective sleep variables and daytime functioning in adults with insomnia. Because treatment of insomnia in older adults is challenging and has limited options, the purpose of ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553778/

データ提供：米国国立医学図書館（NLM）

Daridorexant: A Promising Treatment for Insomnia in Older Adults

Insomnia, a sleep disorder that affects millions, can be particularly challenging for older adults. This study investigates the efficacy and safety of daridorexant, a dual orexin receptor antagonist, in treating insomnia in both older and younger adults.

Daridorexant Shows Potential in Treating Insomnia Across Age Groups

The study found that daridorexant improved both objective and subjective sleep measures in adults with insomnia, regardless of age. The researchers found that daridorexant was well-tolerated and had a similar safety profile in both older and younger adults.

Expanding Treatment Options for Insomnia

This research provides valuable insights into the potential of daridorexant as a safe and effective treatment option for insomnia in older adults. It highlights the need for further research to explore the long-term effects and potential benefits of daridorexant in this patient population.

Dr.Camel's Conclusion

Getting a good night's sleep is essential for overall health and well-being. This study offers a glimmer of hope for older adults struggling with insomnia. It's like finding a cool oasis in a desert of sleepless nights - a source of comfort and improved sleep quality.
Date :
  1. Date Completed 2022-10-13
  2. Date Revised 2022-12-27
Further Info :

Pubmed ID

36098936

DOI: Digital Object Identifier

PMC9553778

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.